Cancer Network – A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy

Rahul Banerjee, Assistant Professor at UW Medicine, shared a post by Cancer Network, on X:

“So much fun speaking with Saad Z. Usmani, Yi Lin, Doris Hansen about CAR-T in MMsm – and the ‘CAR-eligible’ vs ineligible pathways of the future. Although if our shirt colors are any indicator, for an RCT of CAR-T vs ‘investigator’s choice’ we’d all choose the same thing. ”

Quoting Cancer Network‘s post:

“A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy, highlighting BCMA as a target and treatment administration practices.”

Source: Rahul Banerjee/X and Cancer Network/X